<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Diabetes Metab Disord</journal-id><journal-id journal-id-type="iso-abbrev">J Diabetes Metab Disord</journal-id><journal-title-group><journal-title>Journal of Diabetes and Metabolic Disorders</journal-title></journal-title-group><issn pub-type="epub">2251-6581</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29201861</article-id><article-id pub-id-type="pmc">5697100</article-id><article-id pub-id-type="publisher-id">328</article-id><article-id pub-id-type="doi">10.1186/s40200-017-0328-0</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Active phytochemicals of <italic>Pueraria tuberosa</italic> for DPP-IV inhibition: in silico and experimental approach</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Srivastava</surname><given-names>Shivani</given-names></name><address><email>shivanisrivastava07@gmail.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Shree</surname><given-names>Priya</given-names></name><address><email>priyashree.bhu@gmail.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Tripathi</surname><given-names>Yamini Bhusan</given-names></name><address><email>yaminibiochemist6@gmail.com</email><email>yaminiok@yahoo.com</email><email>yamini30@gmail.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1768 1906</institution-id><institution-id institution-id-type="GRID">grid.463154.1</institution-id><institution>Department of Medicinal Chemistry, </institution><institution>Institute of Medical Sciences, Banaras Hindu University, </institution></institution-wrap>Varanasi, U.P India </aff></contrib-group><pub-date pub-type="epub"><day>21</day><month>11</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>21</day><month>11</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>16</volume><elocation-id>46</elocation-id><history><date date-type="received"><day>14</day><month>7</month><year>2017</year></date><date date-type="accepted"><day>15</day><month>11</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">We had earlier reported that the extract of <italic>Pueraria tuberosa</italic> significantly inhibits DPP-IV enzyme, resulting in glucose tolerance response in rats. In this study, we have explored the active phytochemicals responsible for this potential. The results have been validated in both fasting and postprandial states in the plasma of normal rats and also in fasting blood and intestinal homogenates of diabetic models.</p></sec><sec><title>Methods</title><p id="Par2">
<italic>Pueraria tuberosa</italic> water extract (PTWE) was administered to normal Charles Foster rats for 35&#x000a0;days and to diabetic model (65&#x000a0;mg/kg bw) for 10&#x000a0;days. After treatments, oral glucose tolerance test (OGTT) and insulin was done for 90&#x000a0;min, and the changes in the levels of GLP-1, GIP, and DPP-IV activities were monitored in fasting and postprandial states. In the case of the diabetic model, DPP-IV activity was measured in intestinal homogenate and basal insulin in plasma. The components of PTWE were analyzed via HPLC-MS based on their chemical formula, molecular mass, and retention time. Using the molecular docking study, we have selected the top five components having strong binding energy with DPP-IV.</p></sec><sec><title>Results</title><p id="Par3">The increase in secretion of GLP-1 and GIP was significantly higher in the postprandial state when compared to fasting condition. GLP-1 plasma concentration increased by 5.8 and 2.9 folds and GIP increased by 8.7 and 2.4 folds in PTWE and control rats, respectively. In contrast, the postprandial decrease in DPP-IV specific activities was recorded at 2.3 and 1.4 folds. The response in OGTT and insulin was also consistent with these changes. In comparison to diabetic controls, PTWE-administered rats showed decreased DPP-IV activity in the intestine, leading to enhanced basal insulin concentration. Through molecular docking, we found Puerarone and Robinin to be the most potential phytochemicals of PTWE for DPP-IV inhibition. Binding energy (kcal/mol) and dissociation constant (pM) of Robinin with DPP-IV protein were found to be 7.543 and 2,957,383.75, respectively. For Puerarone, it was 7.376 and 3,920,309, respectively.</p></sec><sec><title>Conclusions</title><p id="Par4">Thus, this study provides the novel active components that contribute to the DPP-IV inhibitory property of PTWE.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>In silico</kwd><kwd>Postprandial</kwd><kwd>Incretins</kwd><kwd>DPP-iv</kwd><kwd>Oral glucose tolerance test</kwd><kwd>Fasting</kwd><kwd>In vivo</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001407</institution-id><institution>Department of Biotechnology , Ministry of Science and Technology</institution></institution-wrap></funding-source><award-id>p07-547</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par10">In the past few decades, incretin therapy has become one of the most widely used approaches for treating diabetes. It includes two types of medicines, i.e., dipeptidyl peptidase IV (DPP-IV) inhibitors (vildagliptin, sitagliptin, alogliptin, linagliptin and saxagliptin) [<xref ref-type="bibr" rid="CR1">1</xref>] and glucagon-like peptide-1 (GLP-1) receptor agonists (liraglutide, exenatide) [<xref ref-type="bibr" rid="CR2">2</xref>]. Glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 are responsible for the homeostatic regulation of glucose-induced insulin secretion. Their half-life in plasma is less than 2&#x000a0;min. due to their rapid inactivation by ubiquitously found proteolytic enzyme DPP-IV (CD 26). The serine protease DPP-IV cleaves the dipeptides from amino terminus, which includes alanine or proline residue in position 2, thus making the two hormones, GIP and GLP-1, biologically inactive [<xref ref-type="bibr" rid="CR3">3</xref>]. Hence, synthetic preparation or identification of potential natural DPP-IV inhibitors is a crucial target for the treatment of diabetic patients.</p><p id="Par11">With respect to DPP-IV inhibition, several plants like <italic>Allophylus cominia</italic> (AC) [<xref ref-type="bibr" rid="CR4">4</xref>], <italic>Berberis aristata</italic> (BA) [<xref ref-type="bibr" rid="CR5">5</xref>], and <italic>Mangifera indica</italic> (MI) [<xref ref-type="bibr" rid="CR6">6</xref>] have been considered. Active phytochemicals, such as cirsimaritin, hispidulin, naringenin, resveratrol, luteolin, apigenin, flavone, and berberine [<xref ref-type="bibr" rid="CR7">7</xref>&#x02013;<xref ref-type="bibr" rid="CR9">9</xref>], of these plants have been screened through in vivo and in silico parameters. The ancient Ayurvedic approach is considered as the most effective and safest treatment method if taken with proper knowledge of dose and preparations [<xref ref-type="bibr" rid="CR10">10</xref>]. In this regard, many plants against diseases like cardiovascular problems such as hypertension and hyperlipidemia as well as with anti-diabetic potential (e.g., <italic>Trigonella foenum-graecum</italic> [<xref ref-type="bibr" rid="CR11">11</xref>], <italic>Rhuscoriaria</italic> L. [<xref ref-type="bibr" rid="CR12">12</xref>], <italic>Melissa officinalis</italic> [<xref ref-type="bibr" rid="CR13">13</xref>], <italic>Berberis aristata, Tamarindus indica</italic> [<xref ref-type="bibr" rid="CR14">14</xref>]) have been discovered; another such plant is <italic>Pueraria tuberosa</italic> (PT), which reportedly shows positive effects in the treatment of diabetes [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>], nephropathy [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>], and inflammation [<xref ref-type="bibr" rid="CR19">19</xref>]. One of its constituents, i.e., puerarin, has been extensively studied for stress [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>], hyperglycemia [<xref ref-type="bibr" rid="CR22">22</xref>], and incretin pathways [<xref ref-type="bibr" rid="CR23">23</xref>] in diabetes. However, there is limited information on active phytochemical constituents of PT water extracts (PTWE) with respect to DPP-IV inhibition. In our previous work, we have reported the inhibitory effect of PTWE on DPP-IV activity [<xref ref-type="bibr" rid="CR15">15</xref>]<italic>.</italic> In this paper, we have extended our study using the same model of non-diabetic rats for chronic in vivo treatment up to 35&#x000a0;days under fasting and glucose-fed conditions. We correlated the results with the levels of GLP-1, GIP, OGTT and insulin. We also checked the DPP-IV inhibition potential in STZ-induced chronic diabetic model. In addition, we also screened the major phytochemicals for direct DPP-IV inhibitory property through in silico molecular docking.</p></sec><sec id="Sec2"><title>Method</title><sec id="Sec3"><title>Sample preparation</title><p id="Par12">PT roots were purchased from the Ayurvedic Pharmacy, Banaras Hindu University. 30&#x000a0;g powder of PT roots was extracted with 8 volumes of distilled water. When the volume was reduced to its one-fourth, it was filtered with cloth. The total yield obtained by this process was 30% [<xref ref-type="bibr" rid="CR15">15</xref>].</p></sec><sec id="Sec4"><title>Animal design</title><p id="Par13">The protocol was approved by the Institute Ethical Committee, Institute of Medical Sciences, Banaras Hindu University, India. For normal rats study, 12 male Charles Foster rats of the same age group (3&#x02013;4&#x000a0;weeks) were divided into two groups (6 each): group 1 for PTWE and group 2 for control. Group 1was administered PTWE at a dose of 50&#x000a0;mg/100&#x000a0;g bw for 35&#x000a0;days. For diabetic model, 12 male Charles Foster rats were administered STZ (65&#x000a0;mg/kg bw) injection. After 60&#x000a0;days, the diabetic rats (glucose level above 200&#x000a0;mg/dL) were divided into two groups: group 3 as a diabetic control and group 4 for PTWE treatment (Diabetic PTWE). After treatment, the rats were sacrificed along with normal rats (Normal Control) in order to isolate intestine (duodenum). The inner parts of the intestine were washed and homogenized with 1&#x000d7; PBS to prepare 20% homogenate.</p></sec><sec id="Sec5"><title>Chemicals and materials used</title><p id="Par14">DPP-IV fluorometric assay kit, GLP-1&#x000a0;&#x00026;&#x000a0;GIP Enzyme Immunoassay (EIA) Kit and Gly-pro-p-nitroanilide (GPPN) were purchased from Sigma Aldrich.</p></sec><sec id="Sec6"><title>Glucose tolerance test</title><p id="Par15">The rats were administered anesthesia, and their basal blood samples were collected in EDTA-containing tubes. Then they were orally administered PTWE at the dose of 50&#x000a0;mg/100&#x000a0;g bw. After 2&#x000a0;h of PTWE treatment, all the rats were given glucose orally at the dose of 2.5&#x000a0;g/kg bw. Then blood was again collected through tail at 45&#x000a0;min and 90&#x000a0;min following glucose loading. Glucose concentration in blood was determined using glucose strips (S.D check) at every step of blood collection.</p></sec><sec id="Sec7"><title>Insulin</title><p id="Par16">Insulin was measured through Immulite 1000 (Siemens) solid phase, two-site chemiluminescent immunometric assay.</p></sec><sec id="Sec8"><title>GLP-1 and GIP concentration in plasma</title><p id="Par17">GLP-1 and GIP concentrations in blood plasma were measured by their EIA Kit.</p></sec><sec id="Sec9"><title>DPP-IV specific activity in plasma</title><p id="Par18">DPP-IV activity was done by adding 95&#x000a0;&#x003bc;l GPPN (0.2&#x000a0;mM) as substrate in the mixture of 65 &#x003bc;lTrisHCl (50&#x000a0;mM, 7.5 pH) and 10&#x000a0;&#x003bc;l plasma. Absorbance was taken immediately and after 20&#x000a0;min at 405&#x000a0;nm. The protein concentration was measured via the Bradford method.</p></sec><sec id="Sec10"><title>DPP-IV activity in homogenate</title><p id="Par19">DPP-IV activity in homogenates was measured by their respective fluorometric assay kit (Sigma MAK088).</p></sec><sec id="Sec11"><title>Molecular docking</title><p id="Par20">For molecular docking study, the 3D protein structures of DPP-IV (PDB ID-4FFV) were retrieved from the RCSB Protein Data Bank (<ext-link ext-link-type="uri" xlink:href="http://www.rcsb.org">http://www.rcsb.org</ext-link>). The 2D structures of precious phytochemicals (Robinin, Puererone, Anhydrotuberosin, Daidzin, Tuberosin, Puerarin 4&#x02032;,6&#x02032;-diacetate, Tuberostan, Puetuberosanol, Puerarostan, 3-O-methylanhydrotuberosin, Puererin, 4-methoxypuerarin, Stigmasterol, Anthocyanins, Genistin, Hydroxytuberosone, Tectoridin, &#x003b2;-sitosterol, Biochanin A, Biochanin B, Quercetin, Genistein, and Daidzein) from PTWE were retrieved from PubChem compound database (<ext-link ext-link-type="uri" xlink:href="http://pubchem.ncbi.nlm.nih.gov">http://pubchem.ncbi.nlm.nih.gov</ext-link>/) and converted into 3D structure using Discovery Studio 3.0 [<xref ref-type="bibr" rid="CR24">24</xref>]. The protein receptor model was prepared by optimizing protein model geometry and removing ligands and other heteroatoms using the Discovery Studio 3.0. Further, the protein models were taken for active site prediction using Discovery Studio 3.0 and MetaPocket (<ext-link ext-link-type="uri" xlink:href="http://projects.biotec.tu-dresden.de/metapocket/">http://projects.biotec.tu-dresden.de/metapocket/</ext-link>) [<xref ref-type="bibr" rid="CR25">25</xref>] and subjected to docking studies. Molecular docking calculation was done using the YASARA software [<xref ref-type="bibr" rid="CR26">26</xref>]. For this, 25 selected phytochemicals from PT were taken for docking with DPP-IV. In YASARA, the receptor and ligand files were used to set target and play macro. The macro file dockrun_mcr was used to calculate the interaction between the receptor and the selected ligands individually. There were 25 runs of all the ligands and receptor files for docking calculation. Then the object files (docked complex) were visualized using the YASARA software and converted to PDB files for 2D-3D interaction using Discovery studio 3.0. The result log files obtained from YASARA were used for docking calculation. The docking results were sorted by binding energy [kcal/mol] and dissociation constant [pM]. The compounds with more positive binding energy showed a stronger interaction and inhibition activity with receptors.</p></sec><sec id="Sec12"><title>Statistical analysis</title><p id="Par21">Statistical analysis was determined by one-way ANOVA following post hoc test using Dunnett&#x02019;s and Tuckey test by IBM SPSS Statistics Software.</p></sec></sec><sec id="Sec13"><title>Results</title><sec id="Sec14"><title>Antidiabetic parameters</title><sec id="Sec15"><title>DPP-IV inhibition</title><p id="Par22">As shown in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>, PTWE means PTWE-treated normal rats and Control means Vehicle-treated normal rats. At fasting, the plasma DPP-IV specific activity was higher compared to the postprandial state. After 90&#x000a0;min of glucose administration, a decrease in plasma DPP-IV specific activity was observed at 1.4 folds lower than the fasting stage. Interestingly, in PTWE-treated rats, this postprandial plasma DPP-IV level was 2.3 folds lower than the fasting plasma DPP-IV value (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> (<xref rid="Fig1" ref-type="fig">a</xref>)). This suggests that glucose administration reduces the plasma DPP-IV level, but in the presence of PTWE, this reduction was more significant, indicating higher GLP-1 and GIP values in plasma and better hypoglycemic state in these rats.<fig id="Fig1"><label>Fig. 1</label><caption><p>Comparision of fasting and postprandial effects of PTWE and vehicle in normal rats&#x02019; plasma; (<bold>a</bold>) Percent decrease of&#x000a0;DPP-IV specific activity&#x000a0;from fasting to post-prandial state after&#x000a0;90 min. of glucose load, (<bold>b</bold>) Oral glucose tolerance test up to 90&#x000a0;min, (<bold>c</bold>) glucose-dependent insulinotropic polypeptide (GIP), (<bold>d</bold>) glucagon-like peptide-1 (GLP-1) and (<bold>e</bold>) Insulin. Values represented as mean&#x02009;&#x000b1;&#x02009;SD (<italic>n</italic>&#x02009;=&#x02009;6 in each group). *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 compared with fasting group.# <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 compared with control group</p></caption><graphic xlink:href="40200_2017_328_Fig1_HTML" id="MO1"/></fig>
</p><p id="Par23">In the case of diabetic model, the oral administration of PTWE (50&#x000a0;mg/100&#x000a0;g bw) for 10&#x000a0;days significantly reduced the STZ-mediated stress-induced DPP-IV activity in intestinal homogenates (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref> (<xref rid="Fig2" ref-type="fig">a</xref>)). It was observed that after 60&#x000a0;days of STZ injection, the increase in intestinal DPP-IV activity was approximately 1.9 fold as compared to normal control, but in diabetic PTWE group, this increase was 1.3 fold. Thus, the cocktail of PTWE also acts as a potential inhibitor of DPP-IV activity in the case of chronic diabetes.<fig id="Fig2"><label>Fig. 2</label><caption><p>Effect of PTWE in diabetic model of rats; (<bold>a</bold>) DPP-IV activity in intestinal homogenate and (<bold>b</bold>) Plasma insulin. Values represented as mean&#x02009;&#x000b1;&#x02009;SD (<italic>n</italic>&#x02009;=&#x02009;6 in each group). # <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 compared with normal control group. @<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 compared with diabetic control group</p></caption><graphic xlink:href="40200_2017_328_Fig2_HTML" id="MO2"/></fig>
</p></sec></sec><sec id="Sec16"><title>Oral glucose tolerance test</title><p id="Par24">PTWE treatment also enhanced the glucose tolerance capacity measured at 45 and 90&#x000a0;min (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> (<xref rid="Fig1" ref-type="fig">b</xref>)). This suggests that a normal individual after PTWE treatment consumes more carbohydrates, without challenging the threshold of insulin release from the pancreas. In other words, pretreatment with PTWE may reduce the load on pancreas while consuming high carbohydrate diet. Thus, PTWE can be used as a prophylactic measure to prevent the onset of hyperglycemia-mediated stress on the pancreas.</p></sec><sec id="Sec17"><title>Plasma incretin secretion</title><p id="Par25">GLP 1 and GIP in plasma were enhanced after glucose loading. After 90&#x000a0;min of glucose loading, the secretion of GLP-1 was found to be increased by 5.8 folds in the case of PTWE-treated rats and 2.9 folds in control rats. Also for GIP levels, a similar trend was observed with 8.7 and 2.4 folds increase in PTWE-treated rats and control rats, respectively (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> (<xref rid="Fig1" ref-type="fig">c</xref>), (<xref rid="Fig1" ref-type="fig">d</xref>)).</p></sec><sec id="Sec18"><title>Insulin</title><p id="Par26">Area under curve for insulin between basal up to 90&#x000a0;min in PTWE rats was found to be 1.7 folds higher than that in control rats (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>(<xref rid="Fig1" ref-type="fig">e</xref>)).</p><p id="Par27">In comparison to diabetic controls, PTWE significantly increased (1.9 fold) the basal insulin concentration in plasma (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref> (<xref rid="Fig2" ref-type="fig">b</xref>)).</p></sec><sec id="Sec19"><title>Molecular docking</title><p id="Par28">We found that out of the 25 selected phytochemicals from PTWE, only two compounds, namely Robinin and Puererone, showed best interactions with DPP-IV protein. They had binding energy of 7.543&#x000a0;kcal/mol and 7.376&#x000a0;kcal/mol and dissociation constant of 2,957,383.75 pM and 3,920,309 pM, respectively (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Further, Robinin and Puererone were taken for interactive visualization using Discovery studio 3.0. It was found that the active-site amino acid residues GlnC<sup>1</sup>, IleC<sup>2</sup>, ValC<sup>3</sup>, LeuC<sup>4</sup>, AlaC<sup>9</sup>, ThrC<sup>84</sup>, PheC<sup>86</sup>, ProC<sup>95</sup>, ThrC<sup>96</sup>, PheC<sup>97</sup>, GlyC<sup>98</sup>, GlyC<sup>99</sup>, GlyC<sup>100</sup>, ThrC<sup>101</sup>, and LysC<sup>102</sup>of DPP-IV were involved in the interactions with Robinin. The residues GlnC<sup>1</sup>, PheC<sup>97</sup>, and GlyC<sup>100</sup> showed direct interaction and hydrogen bonding with Robinin, suggesting inhibition activity. The Pi-Pi interaction was formed by residue PheC<sup>97</sup> (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>(<xref rid="Fig3" ref-type="fig">a</xref>), (<xref rid="Fig3" ref-type="fig">b</xref>)). For Puererone, the active-site amino acid residues TyrC<sup>35</sup>, GlnC<sup>37</sup>, ProC<sup>43</sup>, ProC<sup>45</sup>, PheC<sup>86</sup>, and PheC<sup>97</sup> of DPP-IV were involved in the interactions. The residue TyrC<sup>35</sup> showed Pi-Pi interaction with Puererone (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>(<xref rid="Fig4" ref-type="fig">a</xref>), (<xref rid="Fig4" ref-type="fig">b</xref>)). The positive binding energies of the two phytochemicals with DPP-IV protein showed that they have strong binding affinity and inhibition activity towards DPP-IV protein.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Binding energy and Dissociation constant of Robinin and Puererone with DPP IV protein</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Compound name</th><th>Binding energy (kcal/mol)</th><th>Dissociation constant (pM)</th></tr></thead><tbody><tr><td>Robinin</td><td>7.543</td><td>2,957,383.75</td></tr><tr><td>Puererone</td><td>7.376</td><td>3,920,309.00</td></tr><tr><td>Anhydrotuberosin</td><td>7.149</td><td>5,750,604.5</td></tr><tr><td>Daidzin</td><td>7.042</td><td>6,888,831.5</td></tr><tr><td>Tuberosin</td><td>6.965</td><td>7,844,898.00</td></tr></tbody></table></table-wrap>
<fig id="Fig3"><label>Fig. 3</label><caption><p>
<bold>a</bold>. 2D structure of Robinin with DPP-IV protein. The residues in light pink color show electrostatic interaction while the green color residues show van der Waals interaction. The residues GlnC<sup>1</sup>, PheC<sup>97</sup>, and GlyC<sup>100</sup> show direct interaction and hydrogen bonding with Robinin, and the residue PheC<sup>97</sup>shows Pi-Pi interaction with Robinin; 3(<bold>b</bold>) 3D structure of Robinin with DPP-IV protein</p></caption><graphic xlink:href="40200_2017_328_Fig3_HTML" id="MO3"/></fig>
<fig id="Fig4"><label>Fig. 4</label><caption><p>
<bold>a</bold>. 2D structure of Puererone with DPP-IV protein. The residues in light pink color show electrostatic interaction while the green color residues show van der Waals interaction. The residue TyrC<sup>35</sup> shows Pi-Pi interaction with Puererone; 4(<bold>b</bold>) 3D structure of Puererone with DPP-IV protein</p></caption><graphic xlink:href="40200_2017_328_Fig4_HTML" id="MO4"/></fig>
</p></sec></sec><sec id="Sec20"><title>Discussions</title><p id="Par29">Through the molecular docking of PTWE phytochemicals obtained by HPLC&#x02013;MS (complete data not shown) with DPP-IV, we found five potential DPP-IV inhibitors, i.e., Robinin, Puererone, Anhydrotuberosin, Daidzin, and Tuberosin (Tables&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>, <xref rid="Tab2" ref-type="table">2</xref>). Of them, Robinin and Puererone showed more positive binding energies with DPP-IV (Figs.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>, <xref rid="Fig4" ref-type="fig">4</xref>). This indicates that the two novel compounds act as DPP-IV inhibitors and could play a vital role in the treatment of diabetes.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Chemical profiling of potential phytochemicals of PTWE obtained by HPLCMS</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Compound name</th><th>Chemical formula</th><th>Molecular mass (g/mol)</th><th>Retention time (minute)</th></tr></thead><tbody><tr><td>Robinin</td><td>C33 H40 O19</td><td>740.664</td><td>3.198</td></tr><tr><td>Puererone</td><td>C20 H16 O5</td><td>336.343</td><td>0.667</td></tr><tr><td>Anhydrotuberosin</td><td>C20 H16 O4</td><td>320.344</td><td>0.525</td></tr><tr><td>Daidzin</td><td>C21 H20 O9</td><td>416.382</td><td>8.32</td></tr><tr><td>Tuberosin</td><td>C20 H18 O5</td><td>338.359</td><td>0.897</td></tr></tbody></table></table-wrap>
</p><p id="Par30">It has been previously studied that plasma DPP-IV activity increases at fasting [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. Fasting DPP-IV activity is more enhanced in type 2 diabetic patients than in normal patients due to uncontrolled hyperglycemia or enhanced CD26 T cell activity response, but the process is not well understood [<xref ref-type="bibr" rid="CR29">29</xref>]. Overall fasting must create a stress response in the body that must be compensated through diet intake. Glucose, the most crucial element present in many diets, is known to be responsible for the secretion of GLP-1 and GIP according to the needs of the healthy body. Thus, after glucose loading, the body has a self-adaptive approach to compensate the excess glucose present in the body by secreting GLP-1 from L cells and GIP from K cells of the intestine. The GLP-1 and GIP bind to their respective receptors, i.e., GLP-1R and GIP&#x02013;R, leading to the activation of insulin signaling pathway [<xref ref-type="bibr" rid="CR3">3</xref>]. In our study, PTWE intensified these glucose regulatory homeostatic properties through DPP-IV inhibition response by 1.64 times (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> (<xref rid="Fig1" ref-type="fig">a</xref>)). PTWE also enhanced GLP-1 plasma secretion by 2 times (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> (<xref rid="Fig1" ref-type="fig">d</xref>)) and plasma GIP by 3.7 times (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> (<xref rid="Fig1" ref-type="fig">c</xref>)), leading to increased insulin secretion and thus, increased glucose tolerance capacity in the body (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> (<xref rid="Fig1" ref-type="fig">b</xref>) &#x00026; (<xref rid="Fig1" ref-type="fig">e</xref>)). Here, PTWE with glucose reduces the stress response provided by fasting more effectively than glucose alone. On the other hand, PTWE also upregulates plasma insulin concentration and inhibits DPP-IV activity in the intestine&#x000a0;of diabetic rats (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). Therefore, this herbal drug provides a hypoglycemic response through DPP-IV inhibition pathway. Flavonoids play a role in DPP-IV inhibition [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR30">30</xref>] and have also been studied as GLP-1 receptor agonists [<xref ref-type="bibr" rid="CR31">31</xref>]. In our previous study, we have proved PTWE as a competitive inhibitor of DPP-IV [<xref ref-type="bibr" rid="CR15">15</xref>]. Through computational modeling study, flavones were found to be competitive inhibitors and dock directly into all three active sites of DPP-IV [<xref ref-type="bibr" rid="CR8">8</xref>]. Thus, the positive binding energy of DPP-IV with active isoflavones Robinin and Puerarone present in PTWE must be the most probable reason this plant tuber acts as a DPP-IV inhibitor. According to an in silico study, Puerarone shows strong affinity to VEGFR 1 and VEGFR 2 along with 93.881% human intestinal absorption [<xref ref-type="bibr" rid="CR32">32</xref>]. This effect of PT on VEGF has been studied in our lab but in kidney nephropathy [<xref ref-type="bibr" rid="CR33">33</xref>]. DPP-IV inhibition has been found to activate CREB and improves signaling pathway of islet vascularization through VEGF-A/VEGFR 2 [<xref ref-type="bibr" rid="CR34">34</xref>]. So, it could be concluded that the constituent Puerarone of PTWE works on angiogenesis through the above pathways involving DPP-IV inhibition and vascular endothelial growth factors. Of the 2000 known flavonoids, Robinin is one of the most common dietary compounds. In the gut, Robinin has been found to be hydrolyzed to kaempferol by fecal flora [<xref ref-type="bibr" rid="CR35">35</xref>]. According to another independent study, kaempferol has the potential to inhibit DPP-IV activity [<xref ref-type="bibr" rid="CR36">36</xref>]. The above studies, thus, suggest that the gut flora plays an important role in DPP-IV inhibition mechanism. It means in the diabetic model, the activity of beneficial microbes gets reduced. Here, we can hypothesize that, in addition to Robinin, PTWE contains some other dietary compounds responsible for enhancing these activities of gut microbes. It has been studied that DPP-IV inhibitor bis-pyranoprenyl isolated from ethyl acetate fraction from aerial parts of <italic>Polygala molluginifolia</italic> contributes to GLP-1 secretion through the stimulation of calcium influx in the intestine. The overall mechanism involves voltage-dependent calcium channels, phospholipase C, protein kinase C, and stored calcium [<xref ref-type="bibr" rid="CR30">30</xref>]. As the compositions of all DPP-IV inhibitory plants found in nature are different, the above-discussed pathway must be the common mechanism, with minor modifications for each plant, through which GLP-1 secretion could be enhanced through DPP-IV inhibition. The minor modifications in the mechanism are based on the phytochemicals found specifically in the plants. So, active phytochemicals like Robinin and Puerarone found in PTWE should be studied individually for their DPP-IV inhibition mechanism. The markedly available DPP-IV inhibitors have many adverse effects such as upper respiratory tract infection, nasopharyngitis, headache, urinary tract infection, and so on [<xref ref-type="bibr" rid="CR37">37</xref>]. PT tubers possess many components such as daidzin, puerarin, puerarone, genistein, puetuberosanol, tuberostan, tuberosin, and puerarin 4&#x02032;,6&#x02032;-diacetate&#x000a0;[<xref ref-type="bibr" rid="CR32">32</xref>]. Thus, the use of PTWE could be more beneficial due to the synergistic response provided by all these phytomolecules and its multi-targeted action on many inflammation and stress-linked diseases discussed above. Thus, PTWE provides the cheapest and safe treatment for diabetes in comparison to synthetic drugs.</p></sec><sec id="Sec21"><title>Conclusions</title><p id="Par31">PTWE enhances the glucose homeostatic potential of body through DPP-IV inhibitory pathway via its active components Robinin and Puerarone. Thus, PTWE and its novel components must be considered as an anti-diabetic drug with respect to DPP-IV inhibition.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>DPP-IV</term><def><p id="Par5">Dipeptidyl Peptidase IV</p></def></def-item><def-item><term>GIP</term><def><p id="Par6">Glucose-Dependent Insulinotropic Polypeptide</p></def></def-item><def-item><term>GLP-1</term><def><p id="Par7">Glucagon Like Peptide-1</p></def></def-item><def-item><term>OGTT</term><def><p id="Par8">Oral Glucose Tolerance Test</p></def></def-item><def-item><term>PTWE</term><def><p id="Par9">
<italic>Pueraria tuberosa</italic> water extract</p></def></def-item></def-list></glossary><ack><p>We are thankful to Mr. Harsh Pandey, Ph.D Scholar of Department of Medicinal Chemistry, IMS, BHU, for his help in sample processing.</p><sec id="FPar1"><title>Funding</title><p id="Par32">Department of Biotechnology (DBT) and University Grant Commission (UGC-RGNFD), Government of India.</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p id="Par33">The data and materials supporting the conclusions of this work are included in the article.</p></sec></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>The whole study was planned by SS and YBT. In vivo work was done by SS. Molecular docking was done and analyzed by PS. Statistical analysis was done by SS. Paper writing was done by SS and YBT. All authors read and approved the final manuscript.</p></notes><notes notes-type="COI-statement"><sec id="FPar3"><title>Ethics approval and consent to participate</title><p id="Par34">The protocol was approved by the Institute Ethical Committee (Dean/2015/CAEC/1266), Institute of Medical Sciences, Banaras Hindu University.</p></sec><sec id="FPar4"><title>Consent for publication</title><p id="Par35">Not Applicable</p></sec><sec id="FPar5"><title>Competing interests</title><p id="Par36">The authors declare that they have no competing interests.</p></sec><sec id="FPar6"><title>Publisher&#x02019;s Note</title><p id="Par37">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Craddy</surname><given-names>P</given-names></name><name><surname>Palin</surname><given-names>H-J</given-names></name><name><surname>Johnson</surname><given-names>KI</given-names></name></person-group><article-title>Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparison</article-title><source>Diabetes Ther</source><year>2014</year><volume>5</volume><fpage>1</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1007/s13300-014-0061-3</pub-id><pub-id pub-id-type="pmid">24664619</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalra</surname><given-names>S</given-names></name><name><surname>Baruah</surname><given-names>MP</given-names></name><name><surname>Sahay</surname><given-names>RK</given-names></name><name><surname>Unnikrishnan</surname><given-names>AG</given-names></name><name><surname>Uppal</surname><given-names>S</given-names></name><name><surname>Adetunji</surname><given-names>O</given-names></name></person-group><article-title>Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: past, present, and future. Indian J</article-title><source>Endocrinol Metab</source><year>2016</year><volume>20</volume><fpage>254</fpage><lpage>267</lpage></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baggio</surname><given-names>LL</given-names></name><name><surname>Drucker</surname><given-names>DJ</given-names></name><name><surname>Andryuk</surname><given-names>PJ</given-names></name><name><surname>Lu</surname><given-names>K</given-names></name><name><surname>Stein</surname><given-names>P</given-names></name><name><surname>Khatami</surname><given-names>H</given-names></name><etal/></person-group><article-title>Biology of incretins: GLP-1 and GIP</article-title><source>Gastroenterology</source><year>2007</year><volume>132</volume><fpage>2131</fpage><lpage>2157</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2007.03.054</pub-id><pub-id pub-id-type="pmid">17498508</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="other">Semaan D. In vitro anti-diabetic and anti-obesity activities of compounds from the Cuban medicinal plant, Allophylus cominia (L.) Sw. University of Strathclyde; 2014.</mixed-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chakrabarti</surname><given-names>R</given-names></name><name><surname>Bhavtaran</surname><given-names>S</given-names></name><name><surname>Narendra</surname><given-names>P</given-names></name><name><surname>Varghese</surname><given-names>N</given-names></name><name><surname>Vanchhawng</surname><given-names>L</given-names></name></person-group><article-title>Sham Shihabudeen MH, et al</article-title><source>Dipeptidyl Peptidase-IV Inhibitory Activity of Berberis aristata</source><year>2011</year><volume>4</volume><fpage>158</fpage><lpage>163</lpage></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yogisha</surname><given-names>S</given-names></name><name><surname>Raveesha</surname><given-names>KA</given-names></name></person-group><article-title>Dipeptidyl Peptidase IV Inhibitory activity of Mangifera Indica</article-title><source>J Nat Prod</source><year>2010</year><volume>3</volume><fpage>76</fpage><lpage>79</lpage></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bower</surname><given-names>AM</given-names></name><name><surname>Real Hernandez</surname><given-names>LM</given-names></name><name><surname>Berhow</surname><given-names>MA</given-names></name><name><surname>de Mejia</surname><given-names>EG</given-names></name></person-group><article-title>Bioactive compounds from culinary herbs inhibit a molecular target for type 2 diabetes management, dipeptidyl peptidase IV</article-title><source>J Agric Food Chem</source><year>2014</year><volume>62</volume><fpage>6147</fpage><lpage>6158</lpage><pub-id pub-id-type="doi">10.1021/jf500639f</pub-id><pub-id pub-id-type="pmid">24881464</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Johnson</surname><given-names>MH</given-names></name><name><surname>Lila</surname><given-names>MA</given-names></name><name><surname>Yousef</surname><given-names>G</given-names></name><name><surname>de Mejia</surname><given-names>EG</given-names></name></person-group><article-title>Berry and citrus phenolic compounds inhibit dipeptidyl peptidase IV: implications in diabetes management</article-title><source>Evid Based Complement Alternat Med</source><year>2013</year><volume>2013</volume><fpage>479</fpage><lpage>505</lpage></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-masri</surname><given-names>IM</given-names></name><name><surname>Mohammad</surname><given-names>MK</given-names></name><name><surname>Tahaa</surname><given-names>MO</given-names></name></person-group><article-title>Inhibition of dipeptidyl peptidase IV (DPP IV) is one of the mechanisms explaining the hypoglycemic effect of berberine</article-title><source>J Enzyme Inhib Med Chem</source><year>2009</year><volume>24</volume><fpage>1061</fpage><lpage>1066</lpage><pub-id pub-id-type="doi">10.1080/14756360802610761</pub-id><pub-id pub-id-type="pmid">19640223</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chauhan</surname><given-names>A</given-names></name><name><surname>Semwal</surname><given-names>DK</given-names></name><name><surname>Mishra</surname><given-names>SP</given-names></name><name><surname>Semwal</surname><given-names>RB</given-names></name></person-group><article-title>Ayurvedic research and methodology: present status and future strategies</article-title><source>Ayu</source><year>2015</year><volume>36</volume><fpage>364</fpage><lpage>369</lpage><pub-id pub-id-type="doi">10.4103/0974-8520.175549</pub-id><pub-id pub-id-type="pmid">27833362</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="other">Yousefi E, Zareiy S, Zavoshy R, Noroozi M, Jahanihashemi H, Ardalani H. Fenugreek: A therapeutic complement for patients with borderline hyperlipidemia: A randomised, double-blind, placebo-controlled, clinical trial. Adv Integr Med. 2017;4:31&#x02013;5.</mixed-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ardalani</surname><given-names>H</given-names></name><name><surname>Moghadam</surname><given-names>MH</given-names></name><name><surname>Rahimi</surname><given-names>R</given-names></name><name><surname>Soltani</surname><given-names>J</given-names></name><name><surname>Mozayanimonfared</surname><given-names>A</given-names></name><name><surname>Moradi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Sumac as a novel adjunctive treatment in hypertension: a randomized, double-blind, placebo-controlled clinical trial</article-title><source>RSC Adv.</source><year>2016</year><volume>6</volume><fpage>11507</fpage><lpage>11512</lpage><pub-id pub-id-type="doi">10.1039/C5RA22840A</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">Jandaghi P, Noroozi M, Ardalani H, Alipour M. Lemon balm: A promising herbal therapy for patients with borderline hyperlipidemia&#x02014;A randomized double-blind placebo-controlled clinical trial. Complement Ther Med. 2016;26:136&#x02013;40.</mixed-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other">Hypoglycemic effects of Berberis aristata and <italic>Tamarindus indica</italic> extracts in vitro. Bull. Fac. Pharmacy, Cairo Univ. 2017;55:91&#x02013;4.</mixed-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Srivastava</surname><given-names>S</given-names></name><name><surname>Koley</surname><given-names>TK</given-names></name><name><surname>Singh</surname><given-names>SK</given-names></name><name><surname>Tripathi</surname><given-names>YB</given-names></name></person-group><article-title>The tuber extract of pueraria tuberosa linn.competitively inhibits dpp-iv activity in normoglycemic rats</article-title><source>Int. J Pharm Pharm Sci</source><year>2015</year><volume>7</volume><fpage>7</fpage><lpage>11</lpage></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tripathi</surname><given-names>AK</given-names></name><name><surname>Kohli</surname><given-names>S</given-names></name></person-group><article-title>Anti-diabetic activity and phytochemical screening of crude extracts of PuerariaTuberosa DC. (FABACEAE) grown in India on STZ -induced diabetic rats. Asian J. Med</article-title><source>Pharm Res</source><year>2013</year><volume>3</volume><fpage>66</fpage><lpage>73</lpage></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tripathi</surname><given-names>YB</given-names></name><name><surname>Shukla</surname><given-names>R</given-names></name><name><surname>Pandey</surname><given-names>N</given-names></name><name><surname>Pandey</surname><given-names>V</given-names></name><name><surname>Kumar</surname><given-names>M</given-names></name></person-group><article-title>An extract of <italic>Pueraria tuberosa</italic> tubers attenuates diabetic nephropathy by upregulating matrix metalloproteinase-9 expression in the kidney of diabetic rats</article-title><source>J Diabetes</source><year>2017</year><volume>9</volume><fpage>123</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1111/1753-0407.12393</pub-id><pub-id pub-id-type="pmid">26924185</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yadav</surname><given-names>D</given-names></name><name><surname>Kumar</surname><given-names>M</given-names></name><name><surname>Tripathi</surname><given-names>YB</given-names></name></person-group><article-title>Methanolic extract of tubers of Pueraria Tuberosa Linn. Ameliorates glycerol induced acute kidney injury in rats</article-title><source>J Chem Pharm Res</source><year>2016</year><volume>8</volume><fpage>133</fpage><lpage>139</lpage></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tripathi</surname><given-names>Y</given-names></name><name><surname>Pandey</surname><given-names>N</given-names></name><name><surname>Yadav</surname><given-names>D</given-names></name><name><surname>Pandey</surname><given-names>V</given-names></name></person-group><article-title>Anti-inflammatory effect of Pueraria tuberosa extracts through improvement in activity of red blood cell anti-oxidant enzymes</article-title><source>AYU (An Int. Q. J. Res. Ayurveda)</source><year>2013</year><volume>34</volume><fpage>297</fpage><pub-id pub-id-type="doi">10.4103/0974-8520.123131</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>She</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Hong</surname><given-names>Y</given-names></name><name><surname>Haneda</surname><given-names>M</given-names></name><name><surname>Fitzl</surname><given-names>G</given-names></name><etal/></person-group><article-title>Effects of puerarin in STZ-induced diabetic rats by oxidative stress and the TGF-&#x003b2;1/Smad2 pathway</article-title><source>Food Funct</source><year>2014</year><volume>5</volume><issue>5</issue><fpage>944</fpage><lpage>950</lpage><pub-id pub-id-type="doi">10.1039/C3FO60565E</pub-id><pub-id pub-id-type="pmid">24595557</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu-Liang</surname><given-names>X</given-names></name><name><surname>Xiao-Hui</surname><given-names>S</given-names></name><name><surname>Lu</surname><given-names>G</given-names></name><name><surname>Xiang-Liang</surname><given-names>Y</given-names></name><name><surname>Hui-Bi</surname><given-names>X</given-names></name></person-group><article-title>Puerarin protects rat pancreatic islets from damage by hydrogen peroxide</article-title><source>Eur J Pharmacol</source><year>2006</year><volume>529</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2005.10.024</pub-id><pub-id pub-id-type="pmid">16321378</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Shangguan</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><etal/></person-group><article-title>Puerarin protects pancreatic &#x003b2;-cell survival via PI3K/Akt signaling pathway</article-title><source>J Mol Endocrinol BioScientifica</source><year>2014</year><volume>53</volume><fpage>71</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1530/JME-13-0302</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Yao</surname><given-names>D</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Peng</surname><given-names>Y</given-names></name><name><surname>Ding</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Puerarin protects pancreatic &#x003b2;-cells in obese diabetic mice via activation of GLP-1R signaling</article-title><source>Mol Endocrinol</source><year>2016</year><volume>30</volume><fpage>361</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.1210/me.2015-1213</pub-id><pub-id pub-id-type="pmid">26789107</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arora</surname><given-names>N</given-names></name><name><surname>Singh</surname><given-names>VK</given-names></name><name><surname>Shah</surname><given-names>K</given-names></name><name><surname>Pandey-Rai</surname><given-names>S</given-names></name></person-group><article-title>Qualitative and quantitative analysis of 3D predicted arachidonate 15-lipoxygenase-B (15-LOX-2) from Homo Sapiens</article-title><source>Bioinformation</source><year>2012</year><volume>8</volume><fpage>555</fpage><lpage>561</lpage><pub-id pub-id-type="doi">10.6026/97320630008555</pub-id><pub-id pub-id-type="pmid">22829730</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>B</given-names></name></person-group><article-title>MetaPocket: a meta approach to improve protein ligand binding site prediction. Omi. A J</article-title><source>Integr Biol</source><year>2009</year><volume>13</volume><fpage>325</fpage><lpage>330</lpage></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krieger</surname><given-names>E</given-names></name><name><surname>Vriend</surname><given-names>GYASARA</given-names></name></person-group><article-title>View--molecular graphics for all devices--from smartphones to workstations</article-title><source>Bioinformatics</source><year>2014</year><volume>30</volume><fpage>2981</fpage><lpage>2982</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btu426</pub-id><pub-id pub-id-type="pmid">24996895</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryskjaer</surname><given-names>J</given-names></name><name><surname>Deacon</surname><given-names>CF</given-names></name><name><surname>Carr</surname><given-names>RD</given-names></name><name><surname>Krarup</surname><given-names>T</given-names></name><name><surname>Madsbad</surname><given-names>S</given-names></name><name><surname>Holst</surname><given-names>J</given-names></name><etal/></person-group><article-title>Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake</article-title><source>Eur. J. Endocrinol</source><year>2006</year><volume>155</volume><fpage>485</fpage><lpage>493</lpage><pub-id pub-id-type="doi">10.1530/eje.1.02221</pub-id><pub-id pub-id-type="pmid">16914604</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venkatesham</surname><given-names>A</given-names></name><name><surname>Srinivas</surname><given-names>M</given-names></name><name><surname>Krishna</surname><given-names>DR</given-names></name><name><surname>Narayana</surname><given-names>P</given-names></name></person-group><article-title>Differential expression of dipeptidyl peptidase-IV (DPP-IV) in Indian type-2 diabetic population</article-title><source>J Assoc Physicians India</source><year>2009</year><volume>57</volume><fpage>627</fpage><lpage>630</lpage><pub-id pub-id-type="pmid">20213998</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allenki</surname><given-names>V</given-names></name><name><surname>Devarakonda</surname><given-names>RK</given-names></name><name><surname>Anreddy</surname><given-names>RNR</given-names></name><name><surname>Pantam</surname><given-names>N</given-names></name><name><surname>Yellu</surname><given-names>NR</given-names></name></person-group><article-title>Fasting and post prandial monitoring of dipeptidyl peptidase-iv (Dpp-iv) &#x02013; a biomarker to assess incretin response in Type-2 diabetes. Stamford</article-title><source>J Pharm Sci</source><year>2010</year><volume>2</volume><fpage>81</fpage><lpage>85</lpage></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altenhofen</surname><given-names>D</given-names></name><name><surname>da Luz</surname><given-names>G</given-names></name><name><surname>Frederico</surname><given-names>MJS</given-names></name><name><surname>Venzke</surname><given-names>D</given-names></name><name><surname>Brich</surname><given-names>M</given-names></name><name><surname>Vigil</surname><given-names>S</given-names></name><etal/></person-group><article-title>Bis-Pyrano Prenyl Isoflavone improves glucose homeostasis by inhibiting dipeptidyl Peptidase-4 in hyperglycemic rats</article-title><source>J Cell Biochem</source><year>2017</year><volume>118</volume><fpage>92</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1002/jcb.25614</pub-id><pub-id pub-id-type="pmid">27238050</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wootten</surname><given-names>D</given-names></name><name><surname>Simms</surname><given-names>J</given-names></name><name><surname>Koole</surname><given-names>C</given-names></name><name><surname>Woodman</surname><given-names>OL</given-names></name><name><surname>Summers</surname><given-names>RJ</given-names></name><name><surname>Christopoulos</surname><given-names>A</given-names></name><etal/></person-group><article-title>Modulation of the glucagon-like peptide-1 receptor signaling by naturally occurring and synthetic flavonoids</article-title><source>J Pharmacol Exp Ther</source><year>2011</year><volume>336</volume><fpage>540</fpage><lpage>550</lpage><pub-id pub-id-type="doi">10.1124/jpet.110.176362</pub-id><pub-id pub-id-type="pmid">21075839</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asthana</surname><given-names>S</given-names></name><name><surname>Agarwal</surname><given-names>T</given-names></name><name><surname>Singothu</surname><given-names>S</given-names></name><name><surname>Samal</surname><given-names>A</given-names></name><name><surname>Banerjee</surname><given-names>I</given-names></name><name><surname>Pal</surname><given-names>K</given-names></name><etal/></person-group><article-title>Molecular docking and interactions of Pueraria Tuberosa with vascular endothelial growth factor receptors. Indian</article-title><source>J Pharm Sci</source><year>2015</year><volume>77</volume><fpage>439</fpage><lpage>445</lpage></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shukla</surname><given-names>R</given-names></name><name><surname>Pandey</surname><given-names>N</given-names></name><name><surname>Banerjee</surname><given-names>S</given-names></name><name><surname>Tripathi</surname><given-names>YB</given-names></name></person-group><article-title>Effect of extract of Pueraria Tuberosa on expression of hypoxia inducible factor-1&#x003b1; and vascular endothelial growth factor in kidney of diabetic rats</article-title><source>Biomed Pharmacother</source><year>2017</year><volume>93</volume><fpage>276</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2017.06.045</pub-id><pub-id pub-id-type="pmid">28648975</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samikannu</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Lingwal</surname><given-names>N</given-names></name><name><surname>Padmasekar</surname><given-names>M</given-names></name><name><surname>Engel</surname><given-names>FB</given-names></name><name><surname>Linn</surname><given-names>T</given-names></name></person-group><article-title>Dipeptidyl peptidase IV inhibition activates CREB and improves islet vascularization through VEGF-A/VEGFR-2 signaling pathway</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e82639</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0082639</pub-id><pub-id pub-id-type="pmid">24349326</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bokkenheuser</surname><given-names>VD</given-names></name><name><surname>Shackleton</surname><given-names>CH</given-names></name><name><surname>Winter</surname><given-names>J</given-names></name></person-group><article-title>Hydrolysis of dietary flavonoid glycosides by strains of intestinal Bacteroides from humans</article-title><source>Biochem J</source><year>1987</year><volume>248</volume><issue>3</issue><fpage>953</fpage><lpage>956</lpage><pub-id pub-id-type="doi">10.1042/bj2480953</pub-id><pub-id pub-id-type="pmid">3435494</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morikawa</surname><given-names>T</given-names></name><name><surname>Ninomiya</surname><given-names>K</given-names></name><name><surname>Akaki</surname><given-names>J</given-names></name><name><surname>Kakihara</surname><given-names>N</given-names></name><name><surname>Kuramoto</surname><given-names>H</given-names></name><name><surname>Matsumoto</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Dipeptidyl peptidase-IV inhibitory activity of dimeric dihydrochalcone glycosides from flowers of Helichrysum Arenarium</article-title><source>J Nat Med</source><year>2015</year><volume>69</volume><fpage>494</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1007/s11418-015-0914-8</pub-id><pub-id pub-id-type="pmid">25921859</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pathak</surname><given-names>R</given-names></name><name><surname>Bridgeman</surname><given-names>MB</given-names></name></person-group><article-title>Dipeptidyl Peptidase-4 (DPP-4) inhibitors in the Management of Diabetes</article-title><source>P T MediMedia</source><year>2010</year><volume>35</volume><fpage>509</fpage><lpage>513</lpage></element-citation></ref></ref-list></back></article>